title: Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
abstract: During the mid-nineties, 95-97% of intra-abdominal infection (IAI)- associated microbes were susceptible to commonly used antibiotics. Nowadays, in Gram-negative bacilli, β-lactam resistance and the associated co-resistance to other antibiotics leading to multidrug resistance is reaching crisis proportions. This is a critical issue in the treatment of IAIs, especially for complicated IAIs and for those of nosocomial origin in severely ill patients. In this setting, this article reviews the place in the therapeutic armamentarium of ceftolozane/tazobactam, a new cephalosporin/β-lactamase inhibitor with good activity against extended spectrum β-lactamase producing Enterobacteriaceae, with stability to AmpC β-lactamases and good anti-pseudomonal activity being stable against the most common resistance mechanisms driven by mutation in Pseudomonas aeruginosa. A profound review of its in vitro activity, in vivo efficacy in animal models, pharmacodynamics, pharmacokinetics, clinical efficacy in clinical trials in complicated IAIs and safety data is performed.
authors.affiliation: Department of Anesthesiology and Surgical Critical Care, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.
authors.forename: Emilio
authors.initials: E
authors.lastname: Maseda
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Aguilar
authors.forename: Maria-Jose
authors.initials: MJ
authors.lastname: Gimenez
authors.forename: Fernando
authors.initials: F
authors.lastname: Gilsanz
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D004338:Drug Combinations; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D059413:Intraabdominal Infections / Q000188:drug therapy* / Q000382:microbiology; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D065093:beta-Lactamase Inhibitors; C519491:ceftolozane; D010397:Penicillanic Acid; D000078142:Tazobactam
keywords: AmpC; Pseudomonas aeruginosa; ceftolozane/tazobactam; complicated intra-abdominal infections; enterobacteriaceae; extended-spectrum β-lactamases